Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcella Tazzari

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Nutrients|July 2, 2021
Effects of a Diet Based on Foods from Symbiotic Agriculture on the Gut Microbiota of Subjects at Risk for Metabolic SyndromeSilvia Turroni, Elisabetta Petracci, Valeria Edefonti, et al.
Cytotherapy|July 24, 2024
Dendritic cell vaccines as cancer treatment: focus on 13 years of manufacturing and quality control experience in advanced therapy medicinal productsAnna Maria Granato, Elena Pancisi, Claudia Piccinini, et al.
Molecular Cancer Research : MCR|June 4, 2016
Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial-Mesenchymal Transition-like Process and 22q LossSilvia Stacchiotti, Annalisa Astolfi, Alessandro Gronchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2015
Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP)Silvia Stacchiotti, Maria A Pantaleo, Tiziana Negri, et al.
BMC Cancer|November 22, 2025
CombiCoR-Vax trial: study protocol for a phase II, single-arm, multicenter trial of sequential pembrolizumab plus dendritic cell vaccine followed by trifluridine/tipiracil and bevacizumab in refractory microsatellite-stable metastatic colorectal cancerAlessandro Passardi, Francesco Giulio Sullo, Alessandro Bittoni, et al.
Journal of Neuro-Oncology|August 16, 2023
Immuno markers in newly diagnosed glioblastoma patients underwent Stupp protocol after neurosurgery: a retrospective seriesLorena Gurrieri, Laura Mercatali, Toni Ibrahim, et al.
Cancer Immunology, Immunotherapy : CII|April 17, 2013
Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell responseChiara Camisaschi, Paola Filipazzi, Marcella Tazzari, et al.
The Journal of Investigative Dermatology|September 10, 2016
Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib TreatmentMarcella Tazzari, Valentina Indio, Barbara Vergani, et al.
International Journal of Molecular Sciences|June 28, 2023
Follicular Lymphoma Microenvironment Traits Associated with Event-Free SurvivalMaria Maddalena Tumedei, Filippo Piccinini, Irene Azzali, et al.
Journal for Immunotherapy of Cancer|February 16, 2021
Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patientsVeronica Huber, Lorenza Di Guardo, Luca Lalli, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Nutrients|July 2, 2021
Effects of a Diet Based on Foods from Symbiotic Agriculture on the Gut Microbiota of Subjects at Risk for Metabolic SyndromeSilvia Turroni, Elisabetta Petracci, Valeria Edefonti, et al.
Cytotherapy|July 24, 2024
Dendritic cell vaccines as cancer treatment: focus on 13 years of manufacturing and quality control experience in advanced therapy medicinal productsAnna Maria Granato, Elena Pancisi, Claudia Piccinini, et al.
Molecular Cancer Research : MCR|June 4, 2016
Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial-Mesenchymal Transition-like Process and 22q LossSilvia Stacchiotti, Annalisa Astolfi, Alessandro Gronchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2015
Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP)Silvia Stacchiotti, Maria A Pantaleo, Tiziana Negri, et al.
BMC Cancer|November 22, 2025
CombiCoR-Vax trial: study protocol for a phase II, single-arm, multicenter trial of sequential pembrolizumab plus dendritic cell vaccine followed by trifluridine/tipiracil and bevacizumab in refractory microsatellite-stable metastatic colorectal cancerAlessandro Passardi, Francesco Giulio Sullo, Alessandro Bittoni, et al.
Journal of Neuro-Oncology|August 16, 2023
Immuno markers in newly diagnosed glioblastoma patients underwent Stupp protocol after neurosurgery: a retrospective seriesLorena Gurrieri, Laura Mercatali, Toni Ibrahim, et al.
Cancer Immunology, Immunotherapy : CII|April 17, 2013
Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell responseChiara Camisaschi, Paola Filipazzi, Marcella Tazzari, et al.
The Journal of Investigative Dermatology|September 10, 2016
Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib TreatmentMarcella Tazzari, Valentina Indio, Barbara Vergani, et al.
International Journal of Molecular Sciences|June 28, 2023
Follicular Lymphoma Microenvironment Traits Associated with Event-Free SurvivalMaria Maddalena Tumedei, Filippo Piccinini, Irene Azzali, et al.
Journal for Immunotherapy of Cancer|February 16, 2021
Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patientsVeronica Huber, Lorenza Di Guardo, Luca Lalli, et al.
Pageof 4